KMDA, IL0010941198

Kamada stock: Company raises 2026 revenue guidance to USD 205-208 million

Published on 11/19/2026 at 01:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Kamada stock investors saw record nine-month revenue and higher adjusted EBITDA. Management also sees double-digit revenue and profitability growth in 2027.

Nine-month growth supports outlook

  • Nine-month revenue reached a record level, while adjusted EBITDA margin was 27 percent.
  • Kamada declared a USD 0.14 per-share dividend and plans detailed 2027 guidance in January.
KMDA, IL0010941198, Illustration mit AI erstellt.

On November 9, 2026, Kamada's announcement reported record nine-month results and raised the company's 2026 financial outlook. Revenue for the first nine months reached USD 152.2 million, while adjusted EBITDA rose to USD 40.9 million.

Higher guidance after strong results

Kamada raised its 2026 revenue guidance to USD 205 million-208 million and its adjusted EBITDA guidance to USD 52 million-54 million. The midpoint of the new ranges represents year-over-year growth of 14 percent for revenue and 26 percent for adjusted EBITDA, according to the company.

Third-quarter revenue increased 11 percent to USD 52.0 million, while net income rose 51 percent to USD 8.0 million. For the first nine months, net income increased 29 percent to USD 21.4 million, or USD 0.37 per diluted share.

Cash flow and product demand

Operating cash flow reached approximately USD 37.6 million in the first nine months, compared with USD 17.9 million a year earlier. Kamada attributed revenue growth primarily to higher KEDRAB sales in the United States, alongside VARIZIG and HEPAGAM sales and stronger distribution revenue.

Management also projected double-digit growth in revenue and profitability for 2027, with detailed guidance planned for January. The company declared a USD 0.14 per-share cash dividend, totaling approximately USD 8.0 million.

Business model and market focus

Kamada is a global biopharmaceutical company based in Israel, focused on specialty plasma-derived therapies for rare and serious conditions. Its marketed portfolio includes KEDRAB, GLASSIA, CYTOGAM, VARIZIG, WINRHO SDF, HEPAGAM B, KAMRAB and equine-based anti-snake venom products. The company also distributes third-party pharmaceutical products in Israel and the Middle East and North Africa region, operates plasma collection centers in Texas and pursues business development and merger opportunities.

Kamada company facts

  • Company: Kamada Ltd.
  • ISIN: IL0010941198
  • Ticker: KMDA
  • Listings: Nasdaq and TASE
  • Reporting period: Nine months ended September 30, 2026
  • Sector: Biopharmaceuticals

Kamada operates within the Israeli market environment represented by the TA-35.

Further reporting and analysis are available on the More news and analyses on Kamada stock page.

Disclaimer...
en | IL0010941198 | KMDA | boerse | 70533162 | bgmi